CTOs on the Move

Osta Biotechnologies

www.ostabiotechnologies.com

 
Osta Biotechnologies Inc. is a Dollard-Des-Ormeaux, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

West Hill Gastroenterology

West Hill Gastroenterology is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Taaneh

Taaneh is engaged in commercializing the use of diamond particles, an inert material, for the authentication, identification and construction of anti-counterfeiting systems. The technology has applications in diverse sectors including the pharmaceutical industry, cosmetics and fragrances, foods, textiles, paint, ink, currency, mechanical components, electronics, and packaging. Taaneh`s IP and patent positions are designed to protect the technology that is the basis for the company`s business plan.

Verinetics

Verinetics is a company that provides the DispenSecur solution for Opioid Medication Management, which offers better control for controlled substances and integrates into existing pharmacy and patient management practices.

HearingLife

HearingLife offers hearing wellness care and hearing aids for people who want to achieve optimal results. For a free hearing assessment call (844) 836-5003.

Virpax Pharmaceuticals

Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)